Other
Liposome Bupivacaine
1
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Liposome Bupivacaine is an early-stage landscape with 1 program across 2 companies. The most active players are TLC Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
5
clinical trials
Completed4 · 80%
Not yet recruiting1 · 20%
Clinical Trials
Trial Activity
Liposome Bupivacaine for ANKLE Blocks
Completed·—·Phase 2·NCT03106545·40 enrolled
Liposome Bupivacaine for WRIST Blocks
Completed·—·Phase 2·NCT03106519·32 enrolled
The Effect of Liposomal Bupivacaine Erector Spinae Plane Block on Postoperative Pain in Patients Undergoing Open Upper Abdominal Surgery: A Randomized, Controlled, Double-Blind Trial
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Preclinical·NCT07667439·148 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)